4.6 Article

Guidelines on the use of irradiated blood components

Journal

BRITISH JOURNAL OF HAEMATOLOGY
Volume 191, Issue 5, Pages 704-724

Publisher

WILEY
DOI: 10.1111/bjh.17015

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

The impact of smoking cessation on multiple sclerosis disease progression

Jeff Rodgers, Tim Friede, Frederick W. Vonberg, Cris S. Constantinescu, Alasdair Coles, Jeremy Chataway, Martin Duddy, Hedley Emsley, Helen Ford, Lennora Fisniku, Ian Galea, Timothy Harrower, Jeremy Hobart, Huseyin Huseyin, Christopher M. Kipps, Monica Marta, Gavin McDonnell, Brendan McLean, Owen R. Pearson, David Rog, Klaus Schmierer, Basil Sharrack, Agne Straukiene, Heather C. Wilson, David Ford, Rod M. Middleton, Richard Nicholas

Summary: The negative impact of smoking in multiple sclerosis is well documented, but there is limited evidence on the benefits of smoking cessation for disease progression. This study found that current smokers had higher disability scores compared to those who had never smoked, and there was no improvement in scores with increasing time since quitting. However, when smokers quit, the rate of motor disability deterioration slowed down to match that of non-smokers. This suggests that smoking cessation is beneficial for people with multiple sclerosis.

BRAIN (2022)

Letter Clinical Neurology

Susac's syndrome as an autoimmune complication of alemtuzumab-associated immune reconstitution

Amir Ahmed, Zi Qi Kok, Alasdair Coles, Daniel J. Scoffings, Sarah J. Crisp

JOURNAL OF NEUROLOGY (2022)

Article Clinical Neurology

Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients

Zoya G. Georgieva, Rainer Doffinger, Dinakantha Kumararatne, Alasdair J. Coles, Claire McCarthy

Summary: Real-world investigation on ocrelizumab recipients showed that the humoral response after a single dose of COVID-19 vaccine is lower than expected in CD20-deplete patients. However, the second vaccine dose was able to convert a significant portion of non-responders to seroconverters, indicating a potential improvement in immunogenicity.

MULTIPLE SCLEROSIS JOURNAL (2022)

Review Clinical Neurology

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

Alasdair J. Coles, Joanne L. Jones, Patrick Vermersch, Anthony Traboulsee, Ann D. Bass, Aaron Boster, Andrew Chan, Giancarlo Comi, Oscar Fernandez, Gavin Giovannoni, Eva Kubala Havrdova, Christopher LaGanke, Xavier Montalban, Celia Oreja-Guevara, Fredrik Piehl, Heinz Wiendl, Tjalf Ziemssen

Summary: In individuals with relapsing-remitting multiple sclerosis (MS) after alemtuzumab, preexisting or treatment-emergent autoimmunity does not increase the risk of subsequent autoimmune disease. Additionally, thyroid autoimmunity after alemtuzumab treatment does not lead to an increased risk of non-thyroid autoimmune adverse events. Post-marketing safety data contribute to a comprehensive understanding of the benefits and risks of alemtuzumab in the field of MS.

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Clinical Neurology

Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England

Afagh Garjani, Sameer Patel, Dhiren Bharkhada, Waqar Rashid, Alasdair Coles, Graham R. Law, Nikos Evangelou

Summary: This study investigated the changes in SARS-CoV-2 infection risk among patients receiving disease-modifying therapies for multiple sclerosis (MS) after vaccination. The results showed that patients taking ocrelizumab or fingolimod had a lower level of protection from the SARS-CoV-2 vaccines compared to the general population.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Article Clinical Neurology

Remyelination in humans due to a retinoid-X receptor agonist is age-dependent

Christopher E. McMurran, Trisha Mukherjee, J. William L. Brown, Andrew W. Michell, Declan T. Chard, Robin J. M. Franklin, Alasdair J. Coles, Nick G. Cunniffe

Summary: Remyelination efficiency decreases with age, particularly in patients with multiple sclerosis. Bexarotene, a retinoid-X receptor agonist, only shortens the visual evoked potential latency in patients under 42 years old and increases the magnetization transfer ratio of deep gray matter lesions in those under 43 years old.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2022)

Editorial Material Medicine, General & Internal

Case reports in the Lancet: From neurophobia to global pandemics

Benjamin O. Devoy, Peter J. Bennett, Alasdair J. Coles, Hani S. Mousa

Summary: Neurology remains the most reported specialty, but Hematology and Rheumatology cases are more often reported by non-specialists. The overall distribution by country has also changed, reflecting recent outbreaks of infectious agents.

CLINICAL CASE REPORTS (2022)

Editorial Material Medicine, General & Internal

Is stem cell transplantation safe and effective in multiple sclerosis?

Basil Sharrack, Jennifer Petrie, Alasdair Coles, John A. Snowden

BMJ-BRITISH MEDICAL JOURNAL (2022)

Article Clinical Neurology

Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses

Edward J. Needham, Alexander L. Ren, Richard J. Digby, Emma J. Norton, Soraya Ebrahimi, Joanne G. Outtrim, Doris A. Chatfield, Anne E. Manktelow, Maya M. Leibowitz, Virginia F. J. Newcombe, Rainer Doffinger, Gabriela Barcenas-Morales, Claudia Fonseca, Michael J. Taussig, Rowan M. Burnstein, Romit J. Samanta, Cordelia Dunai, Nyarie Sithole, Nicholas J. Ashton, Henrik Zetterberg, Magnus Gisslen, Arden Eden, Emelie Marklund, Peter J. M. Openshaw, Jake Dunning, Michael J. Griffiths, Jonathan Cavanagh, Gerome Breen, Sarosh R. Irani, Anne Elmer, Nathalie Kingston, Charlotte Summers, John R. Bradley, Leonie S. Taams, Benedict D. Michael, Edward T. Bullmore, Kenneth G. C. Smith, Paul A. Lyons, Alasdair J. Coles, David K. Menon

Summary: COVID-19 and influenza are both associated with brain injury, particularly in severe cases. The brain injury occurs in the context of dysregulated immune responses, with no single pathogenic mechanism clearly responsible. Blood biomarkers can be used to assess the extent and duration of brain injury.

BRAIN (2022)

Article Biochemistry & Molecular Biology

The serum metabolomic profile of a distinct, inflammatory subtype of acute psychosis

Belinda Lennox, Wenzheng Xiong, Patrick Waters, Alasdair Coles, Peter B. Jones, Tianrong Yeo, Jeanne Tan May May, Ksenija Yeeles, Daniel Anthony, Fay Probert

Summary: Some studies suggest that a proportion of psychosis may have an autoimmune basis, but there is currently no biochemical test able to accurately identify inflammation-related psychosis. In a study of acute psychosis patients, distinct clinical and biochemical phenotypes were found in a subgroup of patients, indicating a potential inflammatory subtype.

MOLECULAR PSYCHIATRY (2022)

Article Clinical Neurology

Remyelination varies between and within lesions in multiple sclerosis following bexarotene

J. William L. Brown, Ferran Prados, Daniel R. Altmann, Baris Kanber, Jonathan Stutters, Nick G. Cunniffe, Joanne L. Jones, Zoya G. Georgieva, Edward J. Needham, Cyrus Daruwalla, Claudia Gandini Wheeler-Kingshott, Peter Connick, Siddharthan Chandran, Robin Franklin, David MacManus, Rebecca Samson, Alasdair Coles, Declan Chard

Summary: This study found that treatment response varies depending on the location and degree of abnormality in patients with multiple sclerosis. The remyelinating effect is more pronounced in gray matter lesions, and the post-processing of whole gray matter lesion measures is simpler and may reduce sample sizes.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2022)

Article Clinical Neurology

Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why?

Gavin Brittain, Alasdair J. Coles, G. Giovannoni, Paolo Antonio Muraro, Jacqueline Palace, Jennifer Petrie, Elisa Roldan, N. J. Scolding, John A. Snowden, Basil Sharrack

Summary: In carefully selected patients, autologous HSCT is a safe and highly effective treatment for immune-mediated neurological disorders. Limited understanding has caused confusion, mistrust, and an increase in health tourism.

PRACTICAL NEUROLOGY (2023)

Article Clinical Neurology

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

Cyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, Eva Kubala Havrdova, Dana Horakova, Raed Alroughani, Cavit Boz, Francesco Patti, Marco Onofrj, Alessandra Lugaresi, Sara Eichau, Marc Girard, Alexandre Prat, Pierre Duquette, Bassem Yamout, Samia J. Khoury, Seyed Aidin Sajedi, Recai Turkoglu, Ayse Altintas, Olga Skibina, Katherine Buzzard, Pierre Grammond, Rana Karabudak, Anneke van der Walt, Helmut Butzkueven, Davide Maimone, Jeannette Lechner-Scott, Aysun Soysal, Nevin John, Julie Prevost, Daniele Spitaleri, Cristina Ramo-Tello, Oliver Gerlach, Gerardo Iuliano, Matteo Foschi, Radek Ampapa, Vincent van Pesch, Michael Barnett, Nevin Shalaby, Marie D'hooghe, Jens Kuhle, Maria Jose Sa, Marzena Fabis-Pedrini, Allan Kermode, Saloua Mrabet, Riadh Gouider, Suzanne Hodgkinson, Guy Laureys, Liesbeth Van Hijfte, Richard Macdonell, Celia Oreja-Guevara, Edgardo Cristiano, Pamela McCombe, Jose Luis Sanchez-Menoyo, Bhim Singhal, Yolanda Blanco, Stella Hughes, Justin Garber, Claudio Solaro, Chris McGuigan, Bruce Taylor, Koen de Gans, Mario Habek, Abdullah Al-Asmi, Simu Mihaela, Tamara Castillo Trivino, Talal Al-Harbi, Juan Ignacio Rojas, Orla Gray, Dheeraj Khurana, Bart Van Wijmeersch, Nikolaos Grigoriadis, Jihad Inshasi, Jiwon Oh, Eduardo Aguera-Morales, Yara Fragoso, Fraser Moore, Cameron Shaw, Seyed Mohammad Baghbanian, Neil Shuey, Barbara Willekens, Todd A. Hardy, Danny Decoo, Angel Perez Sempere, Deborah Field, Ray Wynford-Thomas, Nick G. Cunniffe, Izanne Roos, Charles B. Malpas, Alasdair J. Coles, Tomas Kalincik, J. William L. Brown, MSBase Study Grp

Summary: This study found that early non-disabling relapses in people with RRMS are associated with a higher risk of disability accumulation, which may be mitigated by high-efficacy DMTs. Therefore, treatment decisions should take into account the impact of non-disabling relapses.

MULTIPLE SCLEROSIS JOURNAL (2023)

Editorial Material Clinical Neurology

Chasing MOG antibodies down... assays and lumbar punctures

Alasdair J. Coles

BRAIN (2023)

Article Clinical Neurology

Safety and efficacy with alemtuzumab over 13?years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

Alasdair J. Coles, Anat Achiron, Anthony Traboulsee, Barry A. Singer, Carlo Pozzilli, Celia Oreja-Guevara, Gavin Giovannoni, Giancarlo Comi, Mark S. Freedman, Tjalf Ziemssen, Debora Shiota, Andreea M. Rawlings, Alana T. Wong, Magdalena Chirieac, Xavier Montalban

Summary: The safety risks associated with alemtuzumab treatment decreased over time, and the clinical benefits were maintained for 11-13 years, with most patients not requiring additional courses.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2023)

No Data Available